Piramal Pharma Ltd - 543635 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Intimation under Regulation 30 and 47 of SEBI (Listing Obligations and Disclosure Requirements) Regualtions 2015, Newspaper Advertisment titled Notice of the 3rd Annual General Meeting and E-voting Information. Piramal Pharma Ltd - 543635 - Business Responsibility and Sustainability Reporting (BRSR)
Business Responsibility and Sustanibility Reporting (BRSR) Piramal Pharma Ltd - 543635 - Reg. 34 (1) Annual Report.
Notice of the 3rd Annual General Meeting ('AGM') and Annual Report for the financial year 2022-23 Piramal Pharma Ltd - 543635 - Notice Of The 3Rd Annual General Meeting ('AGM') And Annual Report For The Financial Year 2022-23
Notice of the 3rd Annual General Meeting (''AGM'') and Annual Report for the financial year 2022-23 Piramal Pharma Ltd - 543635 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Intimation for Newspaper Adverstisement for Information regarding 3rd Annual General Meeting (''AGM'') Piramal Pharma Ltd - 543635 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release - Appointment of Mr. Jeffrey Hampton as President & Chief Operating Officer of Piramal Critical Care Piramal Pharma Ltd - 543635 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Caisse De Depot Et Placement Du Quebec Piramal Pharma Ltd - 543635 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 ('Listing Regulations') - Transcript of Conference Call with Investors/Analysts Piramal Pharma Ltd - 543635 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Annual Secretarial Compliance Report for the year ended 31st March, 2023
Piramal Pharma Results Earnings Call for Q4FY23
Conference Call with Piramal Pharma Management and Analysts on Q4FY23 Performance and Outlook. Listen to the full earnings transcript.